Drugs Made In America Acquisition Corp. Enters Definitive Merger Agreement with Power Analytics Global Corp for up to $1 Billion Valuation

summarizeSummary

Drugs Made In America Acquisition Corp. (DMAA) has entered into a definitive merger agreement to combine with Power Analytics Global Corp, an AI and analytics company, targeting a $1 billion valuation but with significant dilution for existing DMAA shareholders.

check_boxKey Events

• Definitive Merger Agreement Signed

  Drugs Made In America Acquisition Corp. (DMAA) entered into a definitive merger agreement with Power Analytics Global Corp (PAGC), an AI and analytics company, on April 29, 2026.

• Target Valuation Highly Conditional

  PAGC is targeted for a $1 billion enterprise valuation, subject to a 'Valuation Milestone Schedule' based on verified revenue contracts, with a floor valuation of $300 million.

• Significant Shareholder Dilution Expected

  Post-closing, former PAGC shareholders are expected to own approximately 90% of the combined entity, with existing DMAA shareholders holding about 10% before further PIPE dilution.

• Minimum Cash and PIPE Financing

  The deal targets a minimum of $30 million in cash at closing (flexible down to $15 million) from the Trust Account and/or PIPE financing.

auto_awesomeAnalysis

This definitive merger agreement is a critical development for Drugs Made In America Acquisition Corp., which recently disclosed a going concern warning and required a shareholder-approved extension for its business combination deadline. While the transaction provides a path for DMAA to become an operating company, existing shareholders will face substantial dilution, with former Power Analytics Global Corp. shareholders expected to own approximately 90% of the combined entity. The target valuation of $1 billion is highly contingent on Power Analytics Global Corp. delivering verified revenue contracts and securing sufficient capital, with a floor valuation of $300 million. Investors should monitor the progress of the PIPE financing and the achievement of revenue contract milestones, as these will significantly impact the final valuation and the combined entity's operational runway.